Efficacy of Quetiapine for Pediatric Delirium

• Status: Terminated
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the safety and efficacy of quetiapine as treatment for pediatric delirium.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium

Exclusion Criteria:

• Age <1

• Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or unarousable).

• current treatment for alcohol withdrawal

• hepatic encephalopathy

• pregnancy

• diagnosis of major depressive disorder or bipolar disorder

• diagnosis of movement disorder

• diagnosis of diabetic ketoacidosis

• baseline QTc >500 milliseconds

• non-English speaking subjects and/or parent/guardian